Jet.AI Withdraws Underwritten Public Offering
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Jet.AI Inc. announced that it has withdrawn the underwritten public offering of its common stock. This reflects the company's belief that current market conditions were not conducive for an offering on terms that would be in the best interests of the company's stockholders.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like JTAI with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on JTAI
Wall Street analysts forecast JTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JTAI is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.255
Low
8.00
Averages
8.00
High
8.00
Current: 0.255
Low
8.00
Averages
8.00
High
8.00
About JTAI
Jet.AI Inc., through its subsidiaries, is principally involved in the sale of fractional and whole interests in aircraft; the sale of jet cards, and operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third-party carriers as well as via the Company’s leased and managed aircraft; direct chartering of its HondaJet aircraft by Cirrus; aircraft brokerage and services. Its booking platforms include CharterGPT, and Ava. Its CharterGPT platform displays a variety of options across private aircraft types in addition to the pricing of its own aircraft, with a range of prices drawn from a list of thousands of aircraft for hire. Its Jet.AI Operator Platform provides and continues to develop a business-to-business (B2B) software platform for a suite of software-as-a-service (SaaS) products termed Jet.AI Operator Platform, which consists of Reroute AI, DynoFlight, and FlightClub-Cirrus Specific.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Procter & Gamble (PG) Stock Rises 2% After Beating EPS Estimates in Mixed Q2 Results
- Market Uptrend: U.S. stocks traded higher this morning, with the Dow Jones gaining around 300 points, or 0.63%, reflecting optimistic sentiment towards economic recovery, which may attract more investor interest.
- P&G's Strong Performance: Procter & Gamble reported Q2 adjusted EPS of $1.88, beating the analyst consensus of $1.86, although quarterly sales of $22.208 billion fell short of the expected $22.282 billion, indicating the company's efforts in cost control amidst mixed results.
- Notable Stock Surges: Shares of 60 Degrees Pharmaceuticals skyrocketed 297% to $7.94 after announcing a partnership with Runway Health to expand pre-departure access to ARAKODA, demonstrating strong market reaction to new collaborations.
- Energy Sector Decline: Despite the overall market rise, energy stocks dipped 0.4% on Wednesday, suggesting potential challenges in supply-demand balance within the sector, prompting investors to monitor future market dynamics.
Continue Reading
Gelteq Ltd Reports 22% Bioavailability Increase in Cannabinoid Oral Gel, Shares Surge 50.1%
- Bioavailability Improvement: Gelteq Ltd's oral gel delivery platform achieved over a 22% increase in bioavailability compared to an FDA-approved oil-based product in preclinical trials, indicating significant technological advantages that could enhance market acceptance and drive future sales growth.
- Stock Surge: Following this positive announcement, Gelteq's shares surged 50.1% in pre-market trading to $1.25, reflecting strong investor confidence in the new technology and its market potential.
- Enhanced Market Competitiveness: By improving product bioavailability, Gelteq not only meets the growing consumer demand but also positions itself more favorably in the competitive pharmaceutical market, potentially driving the company's long-term strategic development.
- Increased Investor Interest: With Gelteq's technological advancements and stock price increase, market attention on its future performance has significantly risen, likely attracting more investors and partners, thereby facilitating the company's capital operations and business expansion.
Continue Reading